Abstract
Objective
The aim of this study was to examine the effect of carbamazepine on the pharmacokinetics of orally administered simvastatin in healthy volunteers.
Methods
In a randomised, two-phase crossover study and a wash out of 2 weeks, 12 healthy volunteers took carbamazepine for 14 days (600 mg daily except 200 mg daily for the first 2 days) or no drug. On day 15, each subject ingested 80 mg simvastatin. Serum concentrations of simvastatin and its active metabolite simvastatin acid were measured up to 24 h.
Results
Carbamazepine decreased the mean total area under the serum concentration–time curve of simvastatin and simvastatin acid by 75% (P<0.001) and 82% (P<0.001), respectively. The mean peak concentrations of both simvastatin and simvastatin acid were reduced by 68% (P<0.01), and half-life of simvastatin acid was shortened from 5.9±0.3 h to 3.7±0.5 h (P<0.01) by carbamazepine.
Conclusion
Carbamazepine greatly reduces the serum concentrations of simvastatin and simvastatin acid, probably by inducing their metabolism. Concomitant administration of carbamazepine and simvastatin should be avoided or the dose of simvastatin should be considerably increased.
Similar content being viewed by others
References
Prueksaritanont T, Gorham LM, Ma B, Liu L, Yu X, Zhao JJ et al (1997) In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P 450s. Drug Metab Dispos 25:1191–1199
Landrum Michalets E (1998) Review of therapeutics. Pharmacotherapy18:84–112
Laroudie C, Salazar DE, Cosson JP, Cheuvart B, Istin B, Girault J et al (2000) Carbamazepine-nefazodone interaction in healthy subjects. J Clin Psychopharmacol 20:46–53
Villikka K, Kivistö KT, Mäenpää H, Joensuu H, Neuvonen PJ (1999) Cytochrome P 450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 66:589–593
Eap CB, Yasui N, Kaneko S, Baumann P, Powell K, Otani K (1999) Effects of carbamazepine coadministration on plasma concentrations of the enantiomers of mianserin and its metabolites. Ther Drug Monit 21:166–170
Lucas RA, Gilfillan DJ, Bergstom RF (1988) A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Pharmacol 54:639–643
Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368–374
Pirmohamed M, Kitteringham NR, Breckenridge AM, Park BK (1992) The effect of the enzyme induction on the cytochrome P 450-mediated bioactivation of carbamazepine by mouse liver microsomes. Biochem Pharmacol 44:2307–2314
Kantola T, Kivistö KT, Neuvonen PJ (1998) Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64:177–182
Neuvonen PJ, Kantola T, Kivistö KT (1998) Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 63:3332–3341
Arnadottir M, Eriksson LO, Thysell H, Karkas JD (1993) Plasma concentration profiles of simvastatin 3-hydroxy-3-metyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without cyclosporin. Nephron 65:410–413
Kantola T, Kivistö KT, Neuvonen PJ (1998) Effect of itraconazole on the pharmacokinetics of atorvastatin. Clin Pharmacol Ther 64:58–65
Segaert MF, De-Soete C, Vandewiele I, Verbanck J (1996) Drug-interaction-induced rhabdomyolysis. Nephrol Dial Transplant 11:1846–1847
Wu CY, Benet LZ, Hebert MF, Gupta SK, Rowland M, Gomez DY et al (1995) Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine. Clin Pharmacol Ther 58:492–497
Backman JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ (2000) Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 68:122–129
Pichard L, Domergue J, Fourtanier G, Koch P, Schran HF, Maurel P (1996) Metabolism of the new immunosuppressor cyclosporin G by human liver cytochromes P 450. Biochem Pharmacol 51:591–598
Kogan AD, Orensterin S (1990) Lovastatin-induced acute rhabdomyolysis. Postgrad Med J 66:293–296
Duell PB, Connor WE, Illingworth DR (1998) Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am J Cardiol 81:368–369
Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE (1998) Rhabdomyolysis due to interaction of simvastatin with mibefradil. Lancet 351:1929–1930
Jacobson RH, Wang P, Glueck CJ (1997) Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone (letter) JAMA 277:296–297
Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ (2000) Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 68:592–597
Bertilsson L, Tybring G, Widen J, Chang M, Tomson T (1997) Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Pharmacol 44:186–189
Tateishi T, Masako A, Nakura H, Watanabe M, Tanaka M, Kumai T, Kobayashi S (1999) Carbamazepine induces multiple cytochrome P 450 subfamilies in rats. Chemico-Biological Interactions117:257–268
Baciewicz AM (1986) Carbamazepine drug interaction. Ther Drug Monit 8:305–317
Iwahashi K, Miyatake R, Suwaki H, Hosokawa K, Ichikawa Y (1995) The drug–drug interaction effects of haloperidol on plasma carbamazepine levels. Clin Neuropharmacol 18:233–236
Jerling M, Lindström L, Bondesson U, Bertilsson L (1994) Fluvoxamine inhibition and carbamazepine induction of the metabolism of clozapine: evidence from a therapeutic drug monitoring service. Ther Drug Monit 16:368–374
Ketter TA, Jenkins JB, Schroeder DH, Pazzaglia PJ, Marangell LB, George MS et al (1995) Carbamazepine but not valproate induces bupropion metabolism. J Clin Psychopharmacol 15:327–333
Bertilsson L, Höjer B, Tybring G, Osterloh J, Rane A (1980) Autoinduction of carbamazepine metabolism in children studied with a stabile isotope technique. Clin Pharmacol Ther 27:83–88
McNamara PJ, Colburn WA, Gibaldi M (1979) Time course of carbamazepine self-induction. J Pharmocokinet Biopharm 7:63–68
Pitlick WH, Levy RH (1977) Time-dependent kinetics I: exponential autoinduction of carbamazepine in monkeys. J Pharm Sci 66:647–649
Pitlick WH, Levy RH, Troupin AS, Green JR (1976) Pharmacokinetic model to describe self-induced decreases in steady-state concentrations of carbamazepine. J Pharm Sci 65:462–463
Mikati MA, Browne TR, Collin JF (1989) Time course of carbamazepine autoinduction. The VA Cooperative Study No.118 Group. Neurology 39:592–594
Scheyer RD, Cramer JA, Mattson RH (1994) A pharmacodynamic approach to the estimate of carbamazepine autoinduction. J Pharm Sci 84:491–494
Murphy MJ, Dominiczak MH (1999) Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J 75:359–360
Acknowledgements
We thank Ms. Kerstin Granberg for excellent technical assistance. Supported by grants from the Faculty of Medicine, University of Umeå and scientific council of Jönköping, Sweden, and the Helsinki University Central Hospital Research Fund and the National Technology Agency (Tekes), Finland.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ucar, M., Neuvonen, M., Luurila, H. et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Clin Pharmacol 59, 879–882 (2004). https://doi.org/10.1007/s00228-003-0700-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-003-0700-5